ResearchDx Will Be Exhibiting At AMP 2021

ResearchDx will be exhibiting at AMP 2021 . Please visit us at booth #327. Additionally, our Chief Medical Officer Dr. Shelly Gunn will present the abstract: “Identification of a Novel Large F13A1 Intragenic Deletion by Targeted Next Generation Sequencing in a Patient with Factor X111 Deficiency.” Please call us at 760 473 4295 to set […]

Read More

Hemophilia—The Royal Disease

Our CAP/CLIA certified lab, PacificDx is partnered with CHOC (Children’s Hospital of Orange County) to identify rare inherited blood disorders in infants and mothers to improve their quality of life. Written by Amanda Nguyen (March 2021) ____________________________________________________________________________________________________________________________________________________ The last royal family of Russia was speculated to be plagued with the “royal bleeding disease” passed down […]

Read More

trio-smart: The New Breathtaking Technology

PacificDX is the only lab certified to run trio-Smart™, a breath test developed by Gemelli™. Along with measuring the standard H2, CH4 and CO2 levels, trio-smart™ is the only BT that also measures hydrogen sulfide. You are at a fancy dinner party wearing your favorite dress. After the delicious meal, you are conversing with an […]

Read More

ResearchDx Partners with Lucid Diagnostics for First DNA Methylation Test for Barrett’s Esophagus

As Lucid Diagnostics’ commercial diagnostic laboratory partner, the new EsoGuard esophageal DNA laboratory-developed test (LDT) was developed and completed CLIA and CAP certification at ResearchDx’s premier molecular laboratory, PacificDx. The first of its kind, this non-invasive DNA test was designed to detect the presence of dysplastic and non-dysplastic Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC) […]

Read More

Negative Gluten ID Test Results can ‘Rule Out’ Celiac Disease in High Risk Populations

Brief:  First degree relatives of individuals with celiac disease are at elevated risk for developing a similarly severe gluten intolerance disorder. However, a quick screening test for the genetic alterations responsible for encoding gluten recognition immune receptors can rule out celiac disease risk in these individuals. Developed by Targeted Genomics, the DNA-based, non-invasive Gluten ID […]

Read More

Molecular Medicine Tri-Con Meeting

Irvine, CA — Jan 28, 2020 — ResearchDx will attend the Molecular Medicine Tri-Con Meeting in San Francisco California, March 1–4. Please visit our booth #600, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show. 

Read More

Blood-Based Biomarkers Discriminate IBS from IBD with High Degree of Certainty in Patients with Chronic Diarrhea

Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — July 18, 2019 — ResearchDx will attend the Association of Molecular Pathology (AMP) in Baltimore, Maryland November 7–9, 2019. Please visit our booth #2967, or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.    

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — Oct 1, 2018 — ResearchDx will attend the Association of Molecular Pathology (AMP) in San Antonio, Texas, November 1–3, 2018. Please visit booth #602, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show.

Read More